ALLO
Allogene Therapeutics Inc

3,227
Mkt Cap
$268.48M
Volume
1.65M
52W High
$3.78
52W Low
$0.8621
PE Ratio
-1.09
ALLO Fundamentals
Price
$1.21
Prev Close
$1.21
Open
$1.20
50D MA
$1.20
Beta
1.58
Avg. Volume
2.89M
EPS (Annual)
-$1.32
P/B
0.77
Rev/Employee
$96.07
Loading...
Loading...
News
all
press releases
TVRD Stock Plunges 84% After Phase II Fibrosis Study Misses Key Goals
Tvardi Therapeutics' shares crater after its phase II idiopathic pulmonary fibrosis study shows no meaningful benefit from TTI-101 therapy compared to placebo.
Zacks·10d ago
News Placeholder
More News
News Placeholder
Zoetis Gains CVMP Backing for Lenivia, Eyes EU Approval in Dog OA Pain
ZTS secures CVMP's positive opinion recommending the approval of Lenivia, a long-acting OA pain therapy for dogs, with the final decision expected in late 2025.
Zacks·10d ago
News Placeholder
TEVA Gets FDA Nod for Uzedy Label Expansion in Bipolar I Disorder
Teva secures FDA approval for Uzedy label expansion to treat adults with bipolar I disorder.
Zacks·11d ago
News Placeholder
CDTX Stock Up on FDA's Breakthrough Therapy Tag for CD388 in Influenza
Cidara Therapeutics wins FDA Breakthrough Therapy tag for CD388 for the prevention of seasonal influenza. Stock rises.
Zacks·13d ago
News Placeholder
OVID Stock Soars 39% in a Month Following Upbeat Epilepsy Study Data
Ovid Therapeutics jumps 39% in a month after phase I epilepsy study data show superior efficacy of its lead candidate, OV329, hinting at best-in-class potential.
Zacks·14d ago
News Placeholder
KALA Stock Crashes 88% in a Month Following Eye Disorder Study Failure
KALA BIO stock plunges 88% after its KPI-012 eye disorder study fails to meet goals, forcing the company to scrap its pipeline and explore strategic options.
Zacks·16d ago
News Placeholder
AstraZeneca's Baxdrostat Meets Goal in Resistant Hypertension Study
AZN's baxdrostat hit the main goal in the phase III Bax24 study, showing significant blood pressure reductions in patients with resistant hypertension.
Zacks·16d ago
News Placeholder
MRK Expands Tulisokibart Program in Three New Inflammatory Diseases
Merck broadens its tulisokibart clinical program with three new phase IIb studies, deepening its reach across immune-mediated inflammatory diseases.
Zacks·17d ago
News Placeholder
Krystal Biotech Stock Up on FDA Nod to Vyjuvek Label Update
KRYS shares jump after the FDA expands Vyjuvek's label to include DEB patients from birth, with added at-home use flexibility.
Zacks·1mo ago
News Placeholder
Why Is Allogene Therapeutics (ALLO) Up 9.4% Since Last Earnings Report?
Allogene Therapeutics (ALLO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·1mo ago

Latest ALLO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.